User Reviews for Tilmanocept to treat Diagnosis and Investigation
Also known as: Lymphoseek
Lymphoseek (tilmanocept): “Conduced first exploratory use in June, 2013 indication cutaneous melanoma, Breslow/3mm. Tilmanocept was well received by the patient with no local. Clearance delay provision <20 min. SLN discovery total <4 min/2 SLN/Path.”
This information is NOT intended to endorse any particular medication. While these reviews might be helpful, they are not a substitute for the expertise, knowledge and judgement of healthcare practitioners.